Parietal headache: causes and treatment

The US Food and Drug Administration (FDA) on Thursday approved the use of recanmab to treat Alzheimer's disease.

What is Alzheimer's disease?

Alzheimer's disease is one of the most common forms of dementia. It affects the brain and causes a decline in daily living skills as the areas of the brain responsible for thinking, memory, and language are gradually affected.

Adohelm is the first treatment to target the underlying pathophysiology of Alzheimer's disease, namely the presence of amyloid beta plaques in the brain.

Green light and final approval for the first drug to slow the progression of Alzheimer's disease

The US Food and Drug Administration (FDA) on Thursday gave final approval to a drug that slows the progression of Alzheimer's disease.

 

The US Food and Drug Administration has given full regulatory approval to Requimbe, which is manufactured by the Japanese company Eisai and the US pharmaceutical company Biogen.

 

While other drugs have so far only targeted symptoms of the progressive disease, Likembe focuses on the beta-amyloid protein in the brain, which is thought to be one of the main causes of Alzheimer's disease.

The drug is given intravenously every two weeks, and experts recommend that patients undergo regular brain scans to monitor side effects.

Sky News reported that clinical trials measured the drug's effectiveness and found that Requimbe slowed the progression of mild cognitive impairment or early Alzheimer's disease by 27% over 18 months.

 

The Chicago-based Alzheimer's Association praised the FDA's decision, and its president and CEO, Joan Pike, said in a statement that the drug "will help people in the early stages of Alzheimer's maintain their independence and give them time to do the things they love."

 

It is worth noting that the cost of treatment with the drug "Likembe" reaches 20,000 British pounds per year or approximately 25,000 US dollars.

 

In the United States, about 6.7 million adults aged 65 and over have Alzheimer's disease, while in the United Kingdom, about 900,000 people have the disease.

Edit This Article